Comparison of digestive and non-digestive neuroendocrine neoplasm patient characteristics and survival in an ENETS Center of Excellence

Vandamme T., De Backer L., Dero I., Galdermans D., Abrams P., Rondou T., Ulenaers M., Mattelaer C., Peeters M., Lybaert W.

On behalf of the Steering Committee and all NET-specialists in NETwerk.


INTRODUCTION AND AIM

Since 2016 both digestive neuroendocrine neoplasms (D-NENs) and non-digestive NENs (ND-NENs) cases are treated within NETwerk, an ENETS Center of Excellence. We compare the patient characteristics and overall survival (OS) data of D-NENs and ND-NENs.

MATERIALS AND METHODS

Patient characteristics of all NEN discussed on the NET specific multidisciplinary tumor board (NET MDT) from April 2016 to November 2019 were prospectively recorded. Median overall survival (OS) was calculated by Kaplan-Meier statistics and compared using Cox Proportional Hazard models.

RESULTS 602 unique NEN patients on NET MDT 79% 21% Digestive NENs Non digestive NENs 48% 25% **NET grade 1** NET grade 2 23% 12% **NET grade 3** 2% 1% **NEC** 16% 35% 3% 1% MINEN Other (incl. Merkel 1% 19% cell carcinoma) Different 36% 34% treatmentplan local vs. NET MDT



CONCLUSIONS

Discussing ND-NENs and D-NENs at the NET MDT leads to treatment change, indicating an added value in both tumor categories. ND-NENs tend to be higher grade than D-NENs, reflected by a poorer OS.